MedTrace Logo

Drug-Related Problems in Neonatal Patients

NCT04899960 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 512

Last updated 2021-09-02

No results posted yet for this study

Summary

Drug-related problems in newborn babies have been reported with a rate of 4-30%. It is estimated that the higher rates of these problems in hospitalized children under the age of two are related to the variety of drugs used and the differences in the age, weight and diagnosis of the patients. In this context, with the clinical parameters and demographic data obtained in the first 24 hours of the patients hospitalized in the neonatal intensive care unit, machine learning algorithms are used to predict the risks that may arise from possible drug-related problems (prescribing and administration errors, side effects and drug-drug interactions) that may occur during hospitalization. The algorithm, which will be created by modeling with a high number of big data pool, is planned to be transformed into a clinical decision support system software that can be used easily in clinical practice with online and mobile applications. By processing the data of the patients to be included in the model, it is aimed to prevent and manage drug-related problems before they occur, as well as to provide cost-effective medşcation treatment to patients hospitalized in the neonatal intensive care unit, together with a reduction in the risk of drug-related mortality and morbidity.

Conditions

  • Neonatal Intensive Care Unit
  • Medication Errors
  • Drug-Related Problems
  • Adverse Drug Event
  • Drug-Drug Interaction
  • Clinical Pharmacy
  • Machine Learning

Interventions

DRUG

Clinical Pharmacist Intervention

Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.

Sponsors & Collaborators

  • Hacettepe University

    lead OTHER

Principal Investigators

  • Nadir Yalçın, MSc · Hacettepe University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Hour
Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04899960 on ClinicalTrials.gov